Lyell Immunopharma began dosing the first patient in its PiNACLE‑H2H Phase‑3 head‑to‑head trial, a milestone that positions the company to compare its dual‑targeting CAR‑T product, ronde‑cel (LYL314), directly against the two leading CAR‑T therapies, liso‑cel and axicabtagene ciloleucel, in patients with relapsed or refractory large B‑cell lymphoma who have already received one line of therapy.
The randomized, controlled study will enroll roughly 400 patients across 200 sites and will administer a 100 × 10⁶ CAR‑T cell dose of ronde‑cel. The primary endpoint is event‑free survival, with overall response rate and safety as key secondary measures. By directly comparing ronde‑cel to approved competitors, the trial could provide the most definitive evidence of relative efficacy and safety, a data set that regulators and payers will scrutinize closely as Lyell moves toward a 2027 Biologics License Application.
Lyell’s financial profile underscores the importance of the trial’s outcome. In the trailing 12 months ending September 30 2025, the company generated $34 000 in revenue and reported a net loss of $342.99 million, while its Q3 2025 earnings were $38.8 million in the negative. The company’s cash balance stood at approximately $320 million, a reserve that will support the trial and future development but also highlights the need for a successful product launch to achieve financial sustainability.
Chief Medical Officer David Shook said the company is "pleased to have underway PiNACLE‑H2H, the first Phase‑3 head‑to‑head CAR‑T therapy trial for patients with large B‑cell lymphoma," adding that the study demonstrates Lyell’s confidence that ronde‑cel could become the best‑in‑class treatment. External experts, including Krish Patel of the Sarah Cannon Research Institute, noted that the dual‑targeting CD19/CD20 approach could overcome antigen‑loss resistance seen with single‑targeted CAR‑T products. Matthew Lunning, a steering‑committee member, highlighted the trial’s design to include the full spectrum of patients currently receiving CD19 CAR‑T therapy and the potential for outpatient treatment based on the safety profile observed to date.
Ronde‑cel has already received Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA, signaling regulatory recognition of its potential to address unmet needs in relapsed or refractory large B‑cell lymphoma. The head‑to‑head trial will also provide comparative data that could influence payer coverage decisions, as payers increasingly demand evidence of superiority or added value over existing CAR‑T options.
With the first patient dosing now underway, Lyell is on track to submit a BLA for ronde‑cel in 2027. The company’s cash runway, while sufficient for the next two years, will depend on the trial’s results and the ability to secure additional funding or a partnership if needed. Investors are watching closely, as the trial’s outcome will shape Lyell’s competitive positioning and long‑term financial prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.